97在线无码免费人妻短视频,国产成人成人A片在线乱码视频,欧美肥老太牲交视频,国产精品爽爽v在线观看无码

English

ENDPOINTSNEWS: On a quest to challenge Novo Nordisk in obesity, transpacific startup picks up $70M — and a pair of seasoned execs

2021-10-13

新聞截圖.png

— AUTHOR: Amber Tong, Senior Editor

— REPRINTED FROM ENDPOINTSNEWS

— ORIGINAL LINK: https://endpts.com/on-a-quest-to-challenge-novo-nordisk-in-obesity-transpacific-startup-picks-up-70m-and-a-pair-of-seasoned-execs/

Four years after starting Terns Pharmaceuticals together in search of an elusive NASH win, Weidong Zhong and Martijn Fenaux are reuniting at a new startup.

On paper, Sciwind Biosciences — which just raised $70 million in Series C cash — employs a similar setup as Terns: Both have embraced the transpacific model, taking root in China but planting flags in the US.

Zhong was tapped to be president of the San Francisco-based subsidiary back in July, on top of assuming the role as chief strategy officer. Weeks later, Fenaux has been appointed SVP, nonclinical development and translational science at the parent company out of Hangzhou — joining the team alongside chief scientific officer Xinle Wu, who brings experience running R&D for both Eli Lilly and Amgen in China.

Whereas Terns is focused on NASH and other liver diseases, Sciwind positions itself as a specialist in metabolic disorders. The three lead candidates all congregate around GLP-1 receptor agonism, a mechanism that Sciwind reckons is relevant across fatty liver, obesity and diabetes.

The new infusion marks Sciwind’s second financing in a year, having bagged $37 million in February to fuel the clinical work underway for XW003 (long-acting GLP-1 peptide analog) in type 2 diabetes and obesity. Topline Phase II data are expected in the second half of 2022.

To reach those massive markets, the biotech would first have to steer past giant rivals like Novo Nordisk, whose GLP-1 peptide analog semaglutide is already approved in the US for both of those indications.

Then there's the follow-on XW004, which is designed for once daily rather than once weekly administration, slated for first-in-human trials later this year; and XW014, a preclinical small molecule GLP-1R agonist.

But IDG Capital, Loyal Valley Capital and LYFE Capital have no trouble believing in Sciwind and founder/CEO Hai Pan, leading the latest round.

国产成人无码精品一区二区 | 国产精品高潮久久AV无码 | 亚洲av永久无码久久久久 | 结衣乳巨码无在线观看 | 精品乱码一区内射人妻无码一区 | 欧美三级片在线视频 | 国产精品一区亚洲 | 一区二区免费a片 | 亚洲一二三专区 偷拍 麻豆 | 美艳娇妻无码在线一区 | 后入白嫩 亚洲无码 | 亚洲国产一区二区三区无码66 | 欧美激情综合五月色丁香 | 91在线视频免费 | 丁香五月激情六月 | 无码一区二区三区999成人精品 | 一级特黄大片在线观看 | 少妇久久久一品二品 | 人人妻人人澡人人爽 | 亚洲熟妇久久国产精7品 | 黄色在线观看视频 | 欧美高潮潮喷出白水A片 | 黄色视频免费观看视频免费观看222分钟 | 中文字幕在线观看视频网 | 影音先锋2021av天堂 | 午夜福利无码视频 | 手机在线成人网站 | www.亚洲高清视频 | 国产精品久久久久免费a∨ 就去色综合网在线成人小说 | 天天躁日日躁狠狠很躁中文字幕 | 国产精品久久久久久 | 禁止18不能看免费不卡视频 | 精品国产 国产 | 天堂网2014av | 四川丰满少妇A级无码 | 精品人妻一区二区三区1 | 国产精品扒开腿做爽爽爽视频 | 亚洲AV无码一区二区三区桃色Suv | 精品国产鲁一鲁一区二区真希友田 | 成人毛片久久毛片免费看蜜月毛片 | 亚洲精品字幕在线观看 |